Evolutionary Chemistry (EC) is a drug discovery methodology developed to efficiently identify lead pharmaceutical compounds from enormous but focused small molecule libraries. The methodology involves biocatalyzed small molecule library assembly, lead compound selection through the application of evolutionary pressures, and amplification of selected compounds. The frequency at which EC-derived drug leads become drugs would be significantly increased if the lead compound selection components of this methodology demanded not only high affinity for the drug target, but also other drug-like properties. For lead compounds that survive functional screens to become drug candidates, favorable absorption, distribution, metabolism, elimination (ADME), and toxicity properties are all critical determinants of clinical success. The goal of the proposed research is to develop and validate ADME-predictive lead compound selection methods that can be integrated into the EC technology. The lead compound selection methods to be investigated would demand that EC-derived lead compounds have, in addition to high drug target affinity, favorable membrane permeability, serum protein affinity, and metabolism properties. The long-term objective of this research endeavor is to meet medical needs through the application of this improved technology to important drug targets.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI052576-01
Application #
6550097
Study Section
Special Emphasis Panel (ZRG1-SSS-L (10))
Program Officer
Litterst, Charles L
Project Start
2002-07-01
Project End
2002-12-31
Budget Start
2002-07-01
Budget End
2002-12-31
Support Year
1
Fiscal Year
2002
Total Cost
$85,000
Indirect Cost
Name
Invenux, Inc.
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80221
Graham, B S; Bunton, L A; Wright, P F et al. (1991) Reinfection of mice with respiratory syncytial virus. J Med Virol 34:7-13
Montefiori, D C; Lefkowitz Jr, L B; Keller, R E et al. (1991) Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. AIDS 5:513-7
Graham, B S; Bunton, L A; Wright, P F et al. (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88:1026-33
Graham, B S; Bunton, L A; Rowland, J et al. (1991) Respiratory syncytial virus infection in anti-mu-treated mice. J Virol 65:4936-42
Montefiori, D C; Zhou, I Y; Barnes, B et al. (1991) Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182:635-43
Tajima, T; Thompson, J; Wright, P F et al. (1990) Evaluation of a reassortant rhesus rotavirus vaccine in young children. Vaccine 8:70-4
Montefiori, D C; Murphey-Corb, M; Desrosiers, R C et al. (1990) Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J Virol 64:5223-5
Graham, B S; Rowland, J M; Modliszewski, A et al. (1990) Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. J Clin Microbiol 28:2608-11
Robinson Jr, W E; Montefiori, D C; Mitchell, W M (1990) Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 175:600-4
Graham, B S; Karzon, D T (1990) Development of an AIDS vaccine. Biological and ethical challenges. Infect Dis Clin North Am 4:223-43

Showing the most recent 10 out of 13 publications